{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Sunil Healthcare Ltd
Sunil Healthcare Ltd is Rated Sell
Sunil Healthcare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 14 October 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 January 2026, providing investors with the latest insights into the company’s performance and outlook.
Sunil Healthcare Ltd is Rated Sell
Sunil Healthcare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 14 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Sunil Healthcare Ltd is Rated Sell
Sunil Healthcare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 14 October 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 December 2025, providing investors with an up-to-date view of the company's fundamentals, valuation, financial trends, and technical outlook.
Why is Sunil Healthcare Ltd falling/rising?
On 24-Dec, Sunil Healthcare Ltd's stock price rose by 2.86% to close at ₹72.00, marking a notable short-term recovery despite the company’s underperformance relative to the broader market over longer periods.
Sunil Healthcare’s Market Assessment Revised Amidst Challenging Fundamentals
Sunil Healthcare has experienced a revision in its market evaluation, reflecting shifts in key analytical parameters that influence investor sentiment. The pharmaceutical and biotechnology microcap’s recent assessment highlights a complex interplay of financial trends, valuation appeal, and technical outlook, set against a backdrop of subdued sector performance and stock returns.
Why is Sunil Healthcare falling/rising?
As of 14-Nov, Sunil Healthcare Ltd's stock price is at 72.00, having increased slightly after a trend reversal following five days of decline. Despite positive financial results, the stock remains below key moving averages and has underperformed significantly over the past year, indicating ongoing challenges in the market.
Is Sunil Healthcare overvalued or undervalued?
As of November 7, 2025, Sunil Healthcare is considered overvalued with a PE Ratio of 44.63 and an EV to EBITDA of 11.04, lagging behind peers like Sun Pharma and Cipla, and has underperformed the Sensex with a year-to-date return of -3.46%.
Is Sunil Healthcare overvalued or undervalued?
As of November 7, 2025, Sunil Healthcare is fairly valued with a PE ratio of 44.63, higher than Sun Pharma but lower than Divi's Laboratories, and has underperformed the Sensex over the past year, indicating it may not be the best value in its sector.
Is Sunil Healthcare overvalued or undervalued?
As of November 7, 2025, Sunil Healthcare is fairly valued with a PE ratio of 44.63, showing short-term resilience with a 1-week return of 4.58%, but has underperformed over the past year with a return of -11.93% compared to the Sensex's 4.62%.
Are Sunil Healthcare latest results good or bad?
Sunil Healthcare's latest results show a return to profitability with a net profit of ₹0.91 crores and improved operating margins, but challenges remain due to low return ratios and high debt levels, raising concerns about long-term sustainability.
How has been the historical performance of Sunil Healthcare?
Sunil Healthcare's historical performance shows a decline in net sales and profits, with net sales dropping from 110.49 Cr in Mar'23 to 83.42 Cr in Mar'25, and profit after tax turning negative from 6.68 Cr to -1.42 Cr. However, cash flow from operating activities improved from 7.00 Cr to 11.00 Cr during the same period.
Sunil Healthcare Q2 FY26: Micro-Cap Pharma Returns to Profit After Three-Quarter Losing Streak
Sunil Healthcare Ltd., India's second-largest manufacturer of empty hard gelatin capsules, has reported a net profit of ₹0.91 crores for Q2 FY26, marking a dramatic turnaround from three consecutive quarters of losses. The Alwar-based pharmaceutical company posted a sequential profit growth of 152.78% compared to ₹0.36 crores in Q1 FY26, though it represents a year-on-year decline of 231.88% from a loss of ₹0.69 crores in Q2 FY25. The stock, trading at ₹73.97 with a market capitalisation of ₹77.00 crores, has declined 1.37% following the results announcement.
Why is Sunil Healthcare falling/rising?
As of 03-Nov, Sunil Healthcare Ltd's stock price is Rs 75.00, up 4.17% today but down 8.87% over the past month and 14.82% year-over-year. Despite today's gains, the stock's year-to-date performance is negative at -3.85%, indicating struggles relative to the broader market.
Why is Sunil Healthcare falling/rising?
As of 27-Oct, Sunil Healthcare Ltd is priced at 72.00, showing a slight increase but trading below key moving averages, indicating a downward trend. Despite a significant profit increase, the stock faces long-term fundamental weaknesses and has underperformed compared to market benchmarks.
Why is Sunil Healthcare falling/rising?
As of 17-Oct, Sunil Healthcare Ltd's stock price is at 73.25, down 1.8% and has underperformed significantly with a -15.33% return over the past year. The stock is trading below key moving averages, indicating a bearish trend, and faces challenges due to weak fundamentals and high debt levels.
Sunil Healthcare Faces Evaluation Shift Amidst Mixed Financial Performance and Market Perception
Sunil Healthcare, a microcap in the Pharmaceuticals & Biotechnology sector, has recently experienced a change in evaluation, reflecting shifts in its trends. The company reported a 5.38% return on capital employed, while long-term growth remains modest. Challenges include a high debt-to-EBITDA ratio and a decline in stock performance over the past year.
Sunil Healthcare's Evaluation Shift Reflects Mixed Short-Term Gains and Long-Term Challenges
Sunil Healthcare, a microcap in the Pharmaceuticals & Biotechnology sector, has recently adjusted its evaluation, reflecting a shift in market sentiment. The company reported strong quarterly performance metrics, including a notable operating profit to interest ratio, while facing longer-term challenges such as modest sales growth and underperformance against market indices.
How has been the historical performance of Sunil Healthcare?
Sunil Healthcare has experienced a declining trend in net sales and profitability, with net sales dropping from 119.16 Cr in Mar'22 to 83.42 Cr in Mar'25. Despite improved operating profit and cash flow, the company reported negative profits before and after tax in Mar'25.
Sunil Healthcare Reports Strong Operating Profit Amid Long-Term Financial Challenges
Sunil Healthcare, a microcap in the Pharmaceuticals & Biotechnology sector, recently experienced a change in evaluation. The company reported strong Q1 FY25-26 results, with a notable rise in operating profit and an improved operating profit to net sales ratio. However, long-term fundamentals reveal challenges in capital efficiency and debt servicing.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
